• Clinical Insights: October 19, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Tavneos™ (avacopan) – New Orphan Drug Approval – October 8, 2021 – ChemoCentryx, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Tavneos™ (avacopan), an… Read more »

  • Clinical Insights: October 12, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Rethymic® (allogeneic processed thymus tissue-agdc) – New Drug Approval – October 8, 2021 – The U.S. Food and Drug Administration approved Rethymic® for the treatment of pediatric patients… Read more »

  • Clinical Insights: October 5, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval No new update. New Formulation Approval No new update. New Indication/Dosage Approval Tecartus® (brexucabtagene autoleucel) Suspension for Intravenous Infusion – New Approved Indication – October 1, 2021 –… Read more »

  • Clinical Insights: September 28, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Opzelura™ (ruxolitinib) Cream – New Drug Approval – September 21, 2021 – Incyte announced that the U.S. Food and Drug Administration (FDA) has approved Opzelura™ (ruxolitinib) cream for the… Read more »

  • Clinical Insights: September 21, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Exkivity™ (mobocertinib) Capsules – New Drug Approval – September 15, 2021 – The Food and Drug Administration granted accelerated approval to mobocertinib (Exkivity™, Takeda Pharmaceuticals, Inc.) for adult patients… Read more »

  • Clinical Insights: September 14, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval No new update. New Formulation Approval No new update. New Indication/Dosage Approval No new update. New/Updated Drug Shortage September 10, 2021 Atropine Sulfate Injection (Currently in Shortage) Bacitracin… Read more »

  • Clinical Insights: September 8, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Trudhesa™ (dihydroergotamine mesylate) Nasal Spray – New Drug Approval – September 3, 2021 –  Impel NeuroPharma, Inc., a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from… Read more »

  • Clinical Insights: August 31, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Tibsovo® (ivosidenib) – New Drug Approval – August 25, 2021 – The Food and Drug Administration approved ivosidenib (Tibsovo®, Servier Pharmaceuticals LLC) for adult patients with previously treated,… Read more »

  • Clinical Insights: August 24, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Comirnaty™ (Pfizer-BioNTech COVID-19 Vaccine) – New Vaccine Approval – August 23, 2021 – The U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been… Read more »

  • Clinical Insights: August 17, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Welireg™ (belzutifan) Tablets – New Drug Approval – August 13, 2021 – The Food and Drug Administration approved belzutifan (Welireg™, Merck), a hypoxia-inducible factor inhibitor for adult patients with… Read more »